Genentech, a member of the Roche Group (OTC: RHHBY) announced that new data from Actemra (tocilizumab) and Rituxan (rituximab) will ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE